Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of afatinib with cetuximab vs afatinib alone in first-line EGFR-mutated NSCLC
2015-003390-15Phase 2Completed
- Sponsor
- IFCT
- Start
- Dec 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in EGFR-mutated non-small cell lung cancer comparing Afatinib with Afatinib + cetuximab (2 arms). Primary endpoint: Time to treatment failure. Started Dec 2015; status: completed.
02
Drugs
afatinibcetuximab
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2015-003390-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003390-15.